髓源性抑制细胞——血液肿瘤的免疫治疗靶点

doi:10.3760/cma.j.issn.1673-422X.2017.04.020

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (4): 313-316.doi: 10.3760/cma.j.issn.1673-422X.2017.04.020

髓源性抑制细胞——血液肿瘤的免疫治疗靶点

刘静静,金财宝,许秀文,朱晓健,孟力

430030武汉，华中科技大学同济医院血液内科

出版日期:2017-04-08 发布日期:2017-05-09
通讯作者: 刘静静 E-mail:1175728047@qq.com
基金资助:
国家自然科学基金（81272422）

Myeloid-derived suppressor cells—immunotherapy targets in hematological malignancies

Liu Jingjing, Jin Caibao, Xu Xiuwen, Zhu Xiaojian, Meng Li.

Department of Hematology, Tongji Hospital of Huazhong University of Science and Technology, Wuhan 430030, China

Online:2017-04-08 Published:2017-05-09
Contact: Liu Jingjing E-mail:1175728047@qq.com
Supported by:
National Natural Science Foundation of China (81272422)

摘要/Abstract

摘要： 近年来，髓源性抑制细胞（MDSC）成为实体瘤和血液肿瘤的研究热点。在肿瘤中，MDSC不仅通过抑制T细胞增殖、破坏自然杀伤细胞功能和上调调节性T细胞水平发挥免疫抑制作用，还可直接发挥促进肿瘤血管生成和肿瘤转移的非免疫方面的作用。MDSC阻碍了抗肿瘤治疗，尤其影响了免疫治疗的疗效，与临床预后不良相关，可作为肿瘤预后的判断指标，为免疫治疗提供了新靶点。

关键词: 免疫抑制剂, 治疗, 髓源性抑制细胞

Abstract: In recent years, the research hot in the field of solid tumor and blood tumor focuses on the myeloid-derived suppressor cells (MDSCs). In tumors, MDSCs not only exert immunosuppression by inhibiting T cell proliferation, destroying the functions of natural killer cells and recruiting regulatory T cells, but also play non-immunosuppression roles in the promotion of angiogenesis and tumor metastasis. All of these hinder the anti-tumor therapy, and particularly affect the curative effect, which are related with a poor clinical prognosis. MDSCs can be used as prognostic markers, which provide new targets for immunotherapy.

Key words: Immunosuppressive agents, Therapy, Myeloid-derived suppressor cells

刘静静,金财宝,许秀文,朱晓健,孟力. 髓源性抑制细胞——血液肿瘤的免疫治疗靶点[J]. 国际肿瘤学杂志, 2017, 44(4): 313-316.

Liu Jingjing, Jin Caibao, Xu Xiuwen, Zhu Xiaojian, Meng Li.. Myeloid-derived suppressor cells—immunotherapy targets in hematological malignancies[J]. Journal of International Oncology, 2017, 44(4): 313-316.

参考文献

［1］ Kumar V, Patel S, Tcyganov E, et al. The nature of myeloid-derived suppressor cells in the tumor microenvironment［J］. Trends Immunol, 2016, 37(3): 208-220. DOI: 10.1016/j.it.2016.01.004. ［2］ De Veirman K, Van Valckenborgh E, Lahmar Q, et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies［J］. Front Oncol, 2014, 4: 349. DOI: 10.3389/fonc.2014.00349. ［3］ Mandruzzato S, Brandau S, Britten CM, et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cyto-metry: results from an interim study［J］. Cancer Immunol Immuno-ther, 2016, 65(2): 161-169. DOI: 10.1007/s00262-015-1782-5. ［4］ Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment［J］. Adv Cancer Res, 2015, 128: 95-139. DOI: 10.1016/bs.acr.2015.04.002. ［5］ Huang B, Pan PY, Li Q, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host［J］. Cancer Res, 2006, 66(2): 1123-1131. DOI: 10.1158/0008-5472. ［6］ Leonard W, Dufait I, Schwarze JK, et al. Myeloidderived suppressor cells reveal radioprotective properties through arginase-induced larginine depletion［J］. Radiother Oncol, 2016, 119(2): 291-299. DOI: 10.1016/j.radonc.2016.01.014. ［7］ Favaloro J, Liyadipitiya T, Brown R, et al. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma［J］. Leuk Lymphoma, 2014, 55(12): 2893-2900. DOI: 10.3109/10428194.2014.904511. ［8］ Sawant A, Ponnazhagan S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis［J］. Cancer Res, 2013, 73(15): 46064610. DOI: 10.1158/0008-5472.CAN-13-0305. ［9］ Gallamini A, Di Raimondo F, La Nasa G, et al. Standard therapies versus novel therapies in Hodgkin lymphoma［J］. Immunol Lett, 2013, 155(12): 56-59. DOI: 10.1016/j.imlet.2013.09.011. ［10］ Liu J, Zhou Y, Huang Q, et al. CD14+HLA-DRlow/- expression: a novel prognostic factor in chronic lymphocytic leukemia［J］. Oncol Lett, 2015, 9(3): 1167-1172. DOI: 10.3892/ol.2014.2808. ［11］ Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs［J］. Blood, 2014, 124(5): 750-760. DOI: 10.1182/blood-2013-12-546416. ［12］ Christiansson L, Sderlund S, Svensson E, et al. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia［J］. PLoS One, 2013, 8(1): e55818. DOI: 10.1371/journal.pone.0055818. ［13］ Giallongo C, Parrinello N, Brundo MV, et al. Myeloid derived suppressor cells in chronic myeloid leukemia［J］. Front Oncol, 2015, 5: 107. DOI: 10.3389/fonc.2015.00107. ［14］ Kittang AO, Kordasti S, Sand KE, et al. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome［J］. Oncoimmunology, 2016, 5(2): e1062208. DOI: 10.1080/2162402X.2015.1062208.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[11]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[12]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	岳红云, 张百红. 肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.
[15]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰. 派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.

髓源性抑制细胞——血液肿瘤的免疫治疗靶点

Myeloid-derived suppressor cells—immunotherapy targets in hematological malignancies

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价